Unknown

Dataset Information

0

Structure-based discovery of potent inhibitors of Axl: design, synthesis, and biological evaluation.

ABSTRACT: Commonly overexpressed in many cancers and associated with tumor growth, metastasis, drug resistance, and poor overall survival, Axl has emerged as a promising target for cancer therapy. However, the availability of new chemical forms for Axl inhibition is limited. Herein, we present the development and characterization of novel Axl inhibitors, including the design, synthesis, and structure-activity relationships (SARs) of a series of diphenylpyrimidine-diamine derivatives. Most of these compounds exhibited remarkable activity against the Axl kinase. In particular, the promising compound m16 showed the highest enzymatic inhibitory potency (IC50 = 5 nM) and blocked multiple tumor cells' proliferation potencies (the CC50 of 4 out of 42 cancer cell lines <100 nM). Furthermore, compound m16 also possessed preferable pharmacokinetic profiles and liver microsome stability. All these favorable results make m16 a good leading therapeutic candidate for further development.

SUBMITTER: Wu S 

PROVIDER: S-EPMC9579923 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Structure-based discovery of potent inhibitors of Axl: design, synthesis, and biological evaluation.

Wu Shuang S   Liao Min M   Li Minxiong M   Sun Mingming M   Xi Ning N   Zeng Youlin Y  

RSC medicinal chemistry 20220720 10

Commonly overexpressed in many cancers and associated with tumor growth, metastasis, drug resistance, and poor overall survival, Axl has emerged as a promising target for cancer therapy. However, the availability of new chemical forms for Axl inhibition is limited. Herein, we present the development and characterization of novel Axl inhibitors, including the design, synthesis, and structure-activity relationships (SARs) of a series of diphenylpyrimidine-diamine derivatives. Most of these compoun  ...[more]

Similar Datasets

Unknown Design, synthesis, and biological evaluation of potent thiosemicarbazone based cathepsin L inhibitors.
| S-EPMC7125537 | biostudies-literature
Unknown Structure-Based Design, Synthesis, and Biological Evaluation of Triazole-Based smHDAC8 Inhibitors.
| S-EPMC7187165 | biostudies-literature
Unknown Structure-Based Design, Synthesis, and Biological Evaluation of Hsp90β-Selective Inhibitors.
| S-EPMC8790780 | biostudies-literature
Unknown Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors.
| S-EPMC3254106 | biostudies-literature
Unknown Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors.
| S-EPMC2112940 | biostudies-other
Unknown Structure-Based Design, Synthesis, and Biological Evaluation of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors.
| S-EPMC4890168 | biostudies-literature
Unknown Discovery of potent STAT3 inhibitors using structure-based virtual screening, molecular dynamic simulation, and biological evaluation.
| S-EPMC10652556 | biostudies-literature
Unknown Structure-based design, synthesis, and biological evaluation of novel pyrimidinone derivatives as PDE9 inhibitors.
| S-EPMC6089849 | biostudies-literature
Unknown Structure-based drug discovery of novel fused-pyrazolone carboxamide derivatives as potent and selective AXL inhibitors.
| S-EPMC10692477 | biostudies-literature
Unknown Discovery of potent and noncovalent KRAS<sup>G12D</sup> inhibitors: Structure-based virtual screening and biological evaluation.
| S-EPMC9815544 | biostudies-literature